Karyopharm is hoping to broaden the label for its first-in-class blood cancer therapy Xpovio to include myelofibrosis, even ...

BIO-Europe Spring arrived in Lisbon, Portugal yesterday, running from 23 rd to 25 th March. Combined with the LSX World ...

MSD is paying $20 million upfront to activate an alliance with Flagship Pioneering's Quotient Therapeutics that will focus on finding new therapeutic targets in inflammatory bowel disease (IBD). The ...

There is reportedly no customer data in the haul. Cybersecurity specialist SOCRadar said that, if the claims are verified, ...

MSD's Keytruda is poised to end a 20-year drought in new advances in NHS treatment for early-stage head and neck cancer, ...

At BIO-Europe Spring 2026 in Lisbon, Portugal web editor Nicole Raleigh sat down with Robert Jacks, CEO of Sparrow ...

Gilead Sciences has built up its position in the hot area of T-cell engagers (TCEs) for autoimmune diseases with an agreement ...

As health systems seek to balance innovation with the need to address sustainability, increasing attention is being paid to ...

Medicines for obesity, diabetes, rare diseases, cancer, and women's health feature among Clarivate's annual round-up of 11 Drugs to Watch this year, but two of them far outstrip the others in sales ...

In its second AI-focused deal in the space of a week, Servier has announced a partnership with Iktos aimed at finding new, small-molecule therapies for a range of diseases, including cancer and ...

AbbVie has secured its fourth FDA approval for Vraylar, adding adjunctive therapy of major depressive disorder (MDD) to a list that includes schizophrenia and manic and depressive episodes in bipolar ...

Digital health company Noom has started offering lower doses of GLP-1 agonist semaglutide, the active ingredient in Novo Nordisk's weight-loss drug Wegovy, at a knock-down price. The 'microdose' ...